ONE Nanotechnologies, LLC
|Speaker:||Dr. Rob Meagley|
|Primary Industry:||Pharma & Biotech|
|Executive Summary:||ONE Nanotechnologies creates innovative technologies for faster, more accurate, and more cost-effective cancer biomarker analysis. This market is estimated at approximately $500 M dollars annually in the US with a predicted 16% average annual growth rate. We are developing and marketing our patent-pending technology for this dynamic market. We are optimizing our devices for the detection of 4 cancers (Lung, Colorectal, Breast, and Ovarian) and Heart disease that make up the lion’s share of disease mortality in the US and the EU.
Our technology uses precisely shaped arrays of fabricated nanostructures instead of fragile biochemical affinity chemistry to separate and amplify desired biomarkers from complex mixtures; eliminating multi-step process, and reliance upon variability of antibodies for affinity. Our approach is faster, more cost effective and more accurate.
ONE Nanotechnologies was initially backed with $25,000 in funds provided by the founder, Dr. Robert P. Meagley. We seek additional funding of two million dollars to establish our facility and pursue our business goals. ONE Nanotechnologies is determined to develop the next generations of our devices to establish a solid market segment share through sales, technology licensing and strategic partnerships with OEMs, biotech and pharmaceutical companies.
|Venture is:||Seed Level|